Research |

 Pancreatic cancer trials

 

1

 

Tissue collection

Precision-Panc: Advancing personalised medicine treatment strategies for pancreatic cancer

Learn More →



Adjuvant

ESPAC 4: A phase 3 trial to compare gemcitabine alone with gemcitabine and capecitabine together after surgery to remove cancer of the pancreas

Learn More →



Locally advanced

SCALOP2: A multi-centre randomised study of induction chemotherapy followed by capecitabine ( /- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer

Learn More →



Metastatic - 1st line

HALO: A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High metastatic (stage 4) Previously Untreated Pancreatic Ductal Adenocarcinoma

Learn More →


PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation

Learn More →


ACELARATE:: A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patients with metastatic pancreatic carcinoma

Learn More →



Metastatic - 2nd line and beyond

ARTIST1 SEQUIOA: Study of AM0010 with FOLFOX compared to FOLFOX alone, second-line treatment in patients with metastatic pancretic cancer

Learn More →


CAMPLEX: To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (Mozobil), at potentially active plasma concentrations and assess its impact on the immune microenvironment in patients with advanced pancreatic, high-grade serous ovarian and colorectal adenocarcinomas (CAM-PLEX)

Learn More →